Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MC1R | Q01726 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32665626 | 0.77 | GAA (0.43) | MC4RALDH1A1LMNAMC1RUSP2 | |
| SCHEMBL32665221 | 0.64 | SOS1 (0.42) | ALDH1A1LMNA | |
| SCHEMBL32665515 | 0.61 | MGLL (0.46) | ALDH1A1LMNACA1CA2MAPT | |
| SCHEMBL32665162 | 0.61 | PTGS1 (0.54) | ALDH1A1TSHRUSP2KDM4EGAA | |
| SCHEMBL13504056 | 0.57 | GAA (0.71) | MC4RALDH1A1L3MBTL1KDM4EGAA | |
| SCHEMBL28967206 | 0.57 | ELANE (0.55) | TSHRL3MBTL1KDM4EPOLBCA1 | |
| SCHEMBL3587537 | 0.56 | GAA (0.65) | MC4RALDH1A1L3MBTL1KDM4EGAA | |
| SCHEMBL32665517 | 0.56 | ELANE (0.59) | ALDH1A1LMNATSHRL3MBTL1USP2 | |
| SCHEMBL28967200 | 0.56 | ELANE (0.59) | ALDH1A1LMNATSHRKDM4EGAA | |
| SCHEMBL32665629 | 0.55 | GAA (0.54) | MC4RALDH1A1LMNATSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | MC4R 4293/4885ALDH1A1 3714/4885LMNA 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.